AOD-9604 Geriatric (65+) Dosing: What Older Adults and Prescribers Need to Know

What Is AOD-9604 and Why Does Age Change Its Use?

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone, specifically amino acids 176 through 191. It was designed to retain the fat-mobilizing properties of growth hormone while eliminating direct GH-receptor binding, which means it does not raise IGF-1 or carry the diabetogenic side-effects associated with full-length GH therapy. In animal studies, Heffernan et al. demonstrated significant lipolytic activity and an anti-obesity effect without receptor-level GH signaling [1].

Aging changes several physiological parameters that directly alter how a peptide like AOD-9604 behaves in the body. Glomerular filtration rate falls by roughly 1 mL/min/1.73m² per year after age 40, so an average 70-year-old carries an eGFR approximately 30 mL/min lower than at peak adult function [2]. Muscle mass declines at 1-2% per year after 50, shifting body composition in ways that affect volume of distribution for hydrophilic peptides [3]. Hepatic blood flow decreases by up to 40% between ages 25 and 75, slowing phase-I metabolism of many compounds [4]. Each of these changes argues for a lower starting dose and a longer observation window before any upward adjustment.

AOD-9604 is dispensed exclusively through 503A compounding pharmacies under a valid prescription. It has never received FDA approval for any indication in humans, and the clinical evidence base remains thin. Prescribers operating in the geriatric space carry a heightened duty of care given this regulatory context.

Recommended Starting Dose for Adults 65 and Older

The geriatric starting dose used in most 503A compounding protocols is 150 mcg subcutaneously once daily, administered in the morning on an empty stomach. This is half the commonly cited 300 mcg adult dose. The rationale is conservative: older adults reach higher peptide exposure at identical doses because of reduced renal clearance and lower lean mass [2].

The HealthRX clinical team applies the following four-step titration ladder for patients aged 65 and older before any dose escalation is approved:

1. Baseline labs: complete metabolic panel, fasting glucose, HbA1c, eGFR, and a DEXA scan for body-composition reference.
2. Weeks 1-4 at 150 mcg: assess for injection-site reactions, orthostatic blood pressure changes, and fasting glucose shifts.
3. Week 4 decision point: if eGFR remains above 45 mL/min/1.73m², fasting glucose has not risen by more than 10 mg/dL, and the patient reports tolerability, the dose may increase to 225 mcg.
4. Week 8 decision point: escalation to 300 mcg is considered only if weeks 4-8 remain uneventful and body-composition trending confirms adipose change on repeat anthropometrics.

No patient aged 65 or older should reach 300 mcg in fewer than 8 weeks under this protocol.

The American Geriatrics Society Beers Criteria 2023 do not list AOD-9604 specifically, because it lacks FDA approval status, but the Beers framework explicitly cautions against growth hormone and growth-hormone secretagogues in older adults due to edema, arthralgia, and glucose dysregulation risk [5]. Prescribers should treat that guidance as a neighboring warning that informs monitoring priorities even if AOD-9604 is technically outside its scope.

How Renal Function Shapes the Dose Decision

Kidney function is the single most important variable in AOD-9604 geriatric dosing. Peptide clearance is substantially renal, and declining eGFR prolongs half-life, increases peak exposure, and raises the risk of any dose-dependent side effects. The National Kidney Foundation defines CKD Stage 3a as eGFR 45-59 and Stage 3b as eGFR 30-44 [6].

For patients with eGFR 45-59 mL/min/1.73m², the 150 mcg starting dose should be maintained for at least 8 weeks before any consideration of escalation, and 300 mcg should generally not be the target ceiling.

For patients with eGFR 30-44 mL/min/1.73m², the risk-benefit calculation changes substantially. The HealthRX medical team does not recommend initiating AOD-9604 in this population outside a monitored clinical research setting, and any prescriber who does should document explicit informed consent noting the absence of pharmacokinetic data in this renal stratum.

For patients with eGFR <30 mL/min/1.73m² (Stage 4-5 CKD), AOD-9604 should not be prescribed. Accumulation risk is unquantifiable and no safety data exist for this group.

Annual eGFR decline in community-dwelling older adults averages 0.96 mL/min/1.73m², though diabetes and hypertension accelerate this considerably [2]. A patient whose eGFR was 52 at initiation may cross into Stage 3b within 12-18 months, requiring dose reduction or discontinuation even if the original prescription was appropriate.

Falls, Fractures, and Injection Safety in Older Adults

Falls are the leading cause of injury death in U.S. adults aged 65 and older, accounting for more than 36,000 deaths annually according to CDC surveillance data [7]. Any intervention that could affect blood pressure, muscle tone, or postural stability warrants a fall-risk screen before prescribing.

AOD-9604 at standard doses has not been shown in human trials to cause orthostatic hypotension directly. However, the peptide is administered subcutaneously, and two indirect mechanisms deserve attention in older patients. First, injection-site bruising in patients on anticoagulants (a common polypharmacy item in older adults) may cause hematoma formation that itself becomes a fall risk if located near weight-bearing anatomy. Second, any new pharmacological agent that subtly shifts fluid balance or energy metabolism could interact with existing antihypertensives, amplifying orthostatic effects.

The American College of Sports Medicine and the CDC both recommend a standardized fall-risk tool before initiating any new injectable therapy in patients aged 65 and older [7]. The Timed Up and Go test takes under 2 minutes and identifies patients at elevated fall risk with reasonable sensitivity. Scores above 12 seconds should prompt a physiotherapy referral before injection training begins.

Injection technique education is not optional in this age group. Subcutaneous self-injection requires adequate hand strength, visual acuity for drawing the dose, and cognitive capacity to follow a medication schedule. Each of these may be compromised in the older patient. A caregiver or nurse visit for the first three injections is standard practice at HealthRX for patients aged 70 and older.

Polypharmacy and Drug Interaction Burden

Adults aged 65 and older take an average of 5.2 prescription medications concurrently, and roughly 39% of community-dwelling older adults take five or more drugs, meeting the standard definition of polypharmacy [8]. AOD-9604 has no published human pharmacokinetic interaction data, which creates a one-sided evidence gap: the absence of data is not evidence of safety.

Clinically, the interactions of greatest concern fall into three categories:

Insulin and oral hypoglycemics. Growth hormone fragments can affect glucose homeostasis. While Heffernan et al. found that AOD-9604 did not produce the IGF-1 elevation or diabetogenic effect seen with full-length GH [1], prescribers should monitor fasting glucose and HbA1c at baseline and at 8 weeks in any patient on insulin, sulfonylureas, or GLP-1 receptor agonists. The ADA Standards of Medical Care in Diabetes 2024 recommend HbA1c monitoring every 3 months during any medication change affecting metabolic pathways [9].

Anticoagulants. Warfarin, apixaban, and rivaroxaban are among the most commonly prescribed drugs in older adults. Subcutaneous injections in patients on therapeutic anticoagulation carry a non-trivial hematoma risk, and providers should assess injection-site rotation and platelet function before prescribing injectables [10].

Thyroid hormone replacement. Levothyroxine is one of the five most commonly prescribed drugs in the U.S. for patients over 65 [8]. Growth hormone axis activity can alter thyroid hormone conversion from T4 to T3. While AOD-9604 does not activate the GH receptor, monitoring TSH at 12 weeks is a low-cost safeguard.

The Screening Tool of Older Persons' Prescriptions (STOPP) criteria, version 3, provides a systematic framework for identifying potentially inappropriate medications in older patients and should be applied before adding AOD-9604 to any existing regimen [11].

Body Composition Goals and Monitoring in the 65+ Population

The primary rationale for considering AOD-9604 in older adults is adipose modulation, specifically reducing visceral and subcutaneous fat in the context of age-related metabolic dysfunction. Visceral adiposity in older adults independently predicts cardiovascular events, with hazard ratios for major cardiac events ranging from 1.24 to 1.57 per standard deviation increase in visceral fat area, even after controlling for BMI [12].

Monitoring body composition via DEXA is the reference standard. A baseline scan before initiation and a repeat scan at 12 weeks allows prescribers to quantify changes in fat mass, lean mass, and bone mineral density. In a geriatric patient, lean mass preservation is as important as fat reduction. If DEXA at 12 weeks shows fat mass reduction but lean mass loss exceeding 0.5 kg, the dose should be reassessed and resistance training integrated into the plan.

Weighing patients monthly is insufficient as a standalone metric. Two patients can present with identical body weight changes while one loses fat and gains lean mass and the other loses muscle. DEXA removes that ambiguity.

The Endocrine Society's clinical practice guideline on growth hormone deficiency in adults, published in the Journal of Clinical Endocrinology and Metabolism, states that body-composition monitoring via DEXA is the accepted standard for tracking response to agents affecting the somatotropic axis [13]. While AOD-9604 operates outside that axis at the receptor level, the monitoring logic carries over.

Deprescribing Considerations: When to Stop

Deprescribing is the systematic process of reducing or discontinuing medications that are no longer providing net benefit or are causing harm. It is a core geriatric care principle supported by the Canadian Deprescribing Network and the AGS [14].

AOD-9604 should be discontinued if any of the following occur:

• No measurable change in fat mass on DEXA at 12 weeks
• eGFR falls below 30 mL/min/1.73m²
• New-onset or worsening glucose dysregulation (fasting glucose rise above 126 mg/dL on two measurements or HbA1c increase above 0.5% from baseline)
• Injection-site complications that cannot be managed with site rotation
• Patient or caregiver inability to maintain safe injection technique
• Patient preference for discontinuation

The question of how long AOD-9604 should be continued if it is working has no trial-level answer for any age group. Most 503A compounding protocols recommend reassessment at 6-month intervals. For geriatric patients, HealthRX recommends quarterly reassessment given the faster rate of physiological change in this population.

The AGS position on pharmacotherapy in older adults emphasizes that the decision to start a medication implies a parallel commitment to monitor its ongoing necessity, a principle that applies with particular weight to compounds lacking long-term human safety data [5].

Informed Consent Standards for Older Adults Receiving AOD-9604

Informed consent for a compounded peptide with limited human trial data carries additional requirements in geriatric practice. Capacity assessment is the first step. The MacArthur Competence Assessment Tool for Treatment (MacCAT-T) is a validated four-domain instrument that takes 15-20 minutes and is appropriate when cognitive status is uncertain [15].

Patients with mild cognitive impairment (MCI) affecting approximately 15-20% of adults over 65, according to Alzheimer's Association data, may still retain decision-making capacity for straightforward medical choices [16]. The informed consent discussion for AOD-9604 should explicitly cover: the investigational status of the compound, the absence of FDA approval, the lack of long-term human safety data, the specific dose being prescribed and why it differs from standard adult dosing, the monitoring schedule, and the conditions under which the prescription will be stopped.

Written documentation of this conversation, signed by the patient or their legally authorized representative, is not optional. It protects both patient and prescriber in a regulatory environment where compounded peptide oversight is actively evolving. The FDA's guidance on 503A compounding pharmacies, updated in 2024, explicitly notes that prescribers bear independent responsibility for verifying the clinical appropriateness of each compounded preparation [17].

Practical Injection Protocol for the 65+ Patient

Subcutaneous injection of AOD-9604 follows the same anatomical sites used for insulin: the anterior abdomen (at least 2 inches from the navel), the outer thigh, and the posterior upper arm. In older adults with reduced subcutaneous fat and thinner skin, a 4 mm or 6 mm needle is preferred over 8 mm or longer options to minimize intramuscular injection risk.

Rotation of injection sites prevents lipohypertrophy, a well-documented complication of repetitive subcutaneous injection at a single site [18]. Lipohypertrophy alters peptide absorption, a pharmacokinetically relevant problem that could produce erratic dosing in a population that already has narrow therapeutic margins.

The medication should be stored at 2-8 degrees Celsius after reconstitution and used within 28 days. Patients with arthritis affecting fine motor control may benefit from auto-injector devices or pre-drawn syringes prepared by a caregiver. Any reconstituted vial left at room temperature for more than 2 hours should be discarded.

Morning administration on an empty stomach aligns with the natural growth hormone pulse pattern and is the standard timing used in most 503A protocols. Patients should wait at least 30 minutes after injection before eating, a window that may require structured meal planning for older adults whose morning routines are medication-dense.

The CDC's immunization injection safety guidelines, while not specific to peptide therapy, establish the gold standard for subcutaneous technique education and are a reasonable reference for training patients and caregivers on proper administration [19].

Summary of Dose Thresholds by Renal Function

The table below consolidates the HealthRX geriatric dosing framework. No large prospective trial has validated these thresholds; they represent consensus-based clinical judgment grounded in established renal pharmacology principles [2][6].

| eGFR (mL/min/1.73m²) | Starting Dose | Maximum Dose | Monitoring Interval | |---|---|---|---| | >60 | 150 mcg daily | 300 mcg daily | Every 8 weeks | | 45-59 | 150 mcg daily | 225 mcg daily | Every 4 weeks | | 30-44 | Not recommended outside monitored research | N/A | N/A | | <30 | Contraindicated | N/A | N/A |

All patients aged 65 and older should have eGFR re-checked at every monitoring visit. A single eGFR value at baseline is not sufficient to characterize renal function trajectory.